Core Insights - The company reported a robust start to Q1 Fiscal 2026, confirming all financial objectives for the year [1][3][20] Financial Performance - Total Revenues reached €308 million in Q1 Fiscal 2026, reflecting a 9.0% organic growth and a 6.6% reported growth compared to Q1 Fiscal 2025 [2][10][26] - Operating revenue was €268 million, up 9.1% organically and 7.5% reported, driven primarily by Employee Benefits [2][12][29] - Float revenue stood at €40 million, showing an 8.5% organic growth and a 0.8% reported growth [2][13][26] Regional Performance - Continental Europe generated €121 million in revenues, with a slight organic decline of 0.4% but a reported growth of 1.4% [2][28] - Latin America saw revenues of €131 million, achieving a significant organic growth of 17.2% and a reported growth of 16.7% [2][28] - The Rest of the World contributed €56 million, with an organic growth of 12.9% but a reported decline of 2.4% [2][28] Business Segments - Employee Benefits revenue reached €271 million, reflecting an 11.2% organic growth and an 8.8% reported growth [2][27] - Other Products & Services generated €37 million, down 4.6% organically and 7.1% reported [2][27] Strategic Initiatives - The company successfully completed acquisitions of Skipr and ProEves, enhancing its multi-benefit offerings in Belgium, France, and India [4][20][19] - A solid M&A pipeline is expected to support long-term growth ambitions [4][19] Market Conditions - The company is navigating a challenging regulatory environment in Brazil but remains confident in its operational and financial performance [5][6] - Employee Benefits business performance was bolstered by strong new client acquisition and a net retention rate of 100% [6][8]

Regulated information Paris, January 5, 2026 DISCLOSURE FISCAL 2026/09 OF TRANSACTIONS ON TREASURY SHARES Period of: December 29, 2025 to January 2, 2026 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8529-Dec-25NL0015001W4928 36013,2716XPAR213800RQNIQT48SEEO85<td style="width:85px;;te ...

Company Overview - Proactive is a financial news publisher that provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The company operates with a team of experienced and qualified news journalists across key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] Market Focus - Proactive specializes in medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - The content delivered by the team includes insights across various sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Technology Utilization - Proactive is committed to adopting technology to enhance its content creation and workflow processes [4] - The company utilizes automation and software tools, including generative AI, while ensuring that all published content is edited and authored by humans [5]

Core Viewpoint - Protalix BioTherapeutics is focused on advancing its innovative pipeline for rare diseases, particularly targeting uncontrolled gout and rare kidney diseases, while maintaining a profitable commercial business through strategic partnerships [2][14]. Pipeline and Product Development - The company is advancing PRX-115 for uncontrolled gout, which has shown a rapid and durable urate-lowering effect in Phase 1 trials, indicating its potential as a differentiated treatment option [3][15]. - PRX-119 is being developed as a long-acting DNase I for treating inflammation and fibrosis in rare kidney diseases, reflecting the company's strategic focus on this area [4][13]. - The company has submitted an Investigational New Drug (IND) application for PRX-115, which has been approved by the FDA, and the first clinical sites are now activated [15]. Commercial Execution and Market Positioning - Protalix has achieved solid performance with its partner Chiesi Global Rare Diseases, particularly with the launch of Elfabrio for Fabry disease, tracking well against core indicators such as treated patient counts and market share [6][7]. - The global Fabry market is projected to reach approximately $3.4 billion by 2030, with Protalix expecting Elfabrio to capture 15% to 20% of this market [7]. - An appeal regarding a negative opinion from the European Medicines Agency on Elfabrio's dosing regimen is underway, with an outcome expected in Q1 2026 [8]. Strategic Partnerships and Collaborations - The company continues to benefit from established revenue streams, including Elelyso, through collaborations with Pfizer and Fundação Oswaldo Cruz, which support its operational resilience [9]. - A recent collaboration with Secarna Pharmaceuticals aims to develop novel therapeutic candidates for rare renal indications using AI technology [15]. Long-Term Growth and Value Creation - Protalix enters 2026 with a profitable commercial foundation and a focused pipeline addressing high unmet medical needs, aiming to create long-term value for patients and shareholders [14]. - The company emphasizes its commitment to delivering meaningful therapies while pursuing strategic partnerships to enhance its impact and scale [5][14].

Core Insights - Pluxee N.V. disclosed transactions on treasury shares for the period from December 22 to December 24, 2025, indicating active management of its share capital [1]. Group 1: Treasury Share Transactions - On December 22, 2025, a total of 60,491 shares were acquired across three platforms, with a daily weighted average price ranging from €12.9644 to €12.9802 [2]. - On December 23, 2025, a total of 61,751 shares were acquired, with a daily weighted average price between €13.0033 and €13.0290 [2]. - On December 24, 2025, a total of 51,155 shares were acquired, with a daily weighted average price ranging from €13.1493 to €13.1824 [2]. Group 2: Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, impacting over 37 million consumers and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee is dedicated to creating a positive impact on local communities and promoting employee well-being [3].

Regulated information Paris, December 22, 2025 DISCLOSURE FISCAL 2026/07 OF TRANSACTIONS ON TREASURY SHARES Period of: December 15 to December 19, 2025 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8515-Dec-25NL0015001W4929 61913,4896XPAR213800RQNIQT48SEEO8515-Dec-2 ...

Core Viewpoint - Pluxee N.V. successfully held its Annual General Meeting of Shareholders, where all resolutions, including financial statements and dividend distribution, were approved [2]. Group 1: Financial Performance - The financial statements for the fiscal year ending August 31, 2025, were adopted, indicating a positive financial performance for Pluxee [2]. - A dividend of EUR 0.38 per ordinary share was approved for Fiscal 2025, reflecting the company's commitment to returning value to shareholders [2]. Group 2: Dividend Payment Schedule - The ex-dividend date is set for December 19, 2025, with the record date on December 22, 2025, and the payment date scheduled for December 23, 2025 [6]. Group 3: Company Overview - Pluxee operates in 28 countries, focusing on Employee Benefits and Engagement, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,600 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants, showcasing its extensive reach and influence in the market [3]. - With over 45 years of experience, Pluxee is dedicated to creating a positive impact on local communities and promoting employee well-being [3].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Insights - Protalix BioTherapeutics and Secarna Pharmaceuticals have entered into a collaboration and option agreement to develop antisense oligonucleotide therapies for rare renal diseases, leveraging Protalix's expertise in rare diseases and Secarna's AI-powered OligoCreator platform [1][2][3] Company Overview - Protalix BioTherapeutics focuses on innovative therapeutics for rare diseases and has developed two enzyme replacement therapies available in multiple markets, utilizing a proprietary plant cell-based expression system called ProCellEx [4][5] - Secarna Pharmaceuticals specializes in oligonucleotide therapeutics and employs its OligoCreator platform to rapidly generate high-quality antisense candidates, aiming to transform untreatable conditions into treatable ones [7] Collaboration Details - The collaboration involves Protalix selecting pharmaceutical targets for rare renal indications, while Secarna will use its OligoCreator platform to design and profile ASO candidates against these targets [2] - Protalix has the option for an exclusive, worldwide license to further develop and commercialize the therapeutic programs resulting from this collaboration [2][3] Strategic Goals - The partnership aims to advance programs from preclinical stages to clinical trials, addressing significant unmet medical needs in the rare kidney disease space [2][3] - Both companies express excitement about the collaboration, highlighting the combination of Secarna's rapid candidate generation and Protalix's experience in bringing therapies to market [3]

Regulated information Paris, December 15, 2025 DISCLOSURE FISCAL 2026/06 OF TRANSACTIONS ON TREASURY SHARES Period of: December 8 to December 12, 2025 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market. Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO851-Dec-25NL0015001W4930 84913,6928XPAR21 ...